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Introduction: Microparticles (MPs) derived from kidney-derived mesenchymal stem cells (KMSCs) have recently
been reported to ameliorate rarefaction of peritubular capillaries (PTC) in ischemic kidneys via delivery of proangiogenic
effectors. This study aimed to investigate whether KMSC-derived MPs show anti-fibrotic effects by ameliorating
endothelial-to-mesenchymal transition (EndoMT) in human umbilical vein endothelial cells (HUVEC) in vitro and by
preserving PTC in kidneys with unilateral ureteral obstruction (UUO) in vivo.
Methods: MPs isolated from the supernatants of KMSC were co-cultured with HUVEC to assess their in vitro biologic
effects on endothelial cells. Mice were treated with MPs via the tail vein after UUO injury to assess their anti-fibrotic and
PTC sparing effects. Renal tubulointerstitial damage and inflammatory cell infiltration were examined with
Masson’s trichrome, F4/80 and α-smooth muscle actin (α-SMA) staining and PTC rarefaction index was determined by
CD31 staining.
Results: KMSC-derived MPs significantly ameliorated EndoMT and improved in vitro proliferation of TGF-β1 treated
HUVEC. In vivo administration of KMSC-derived MPs significantly inhibited EndoMT of PTC endothelial cells and
improved PTC rarefaction in UUO kidneys. Furthermore, administration of KMSC-derived MPs inhibited inflammatory
cell infiltration as well as tubulointerstitial fibrosis in UUO mice as demonstrated by decreased F4/80 and
α-SMA-positive cells and Masson’s trichrome staining, respectively.
Conclusions: Our results suggest that KMSC-derived MPs ameliorate PTC rarefaction via inhibition of EndoMT
and protect against progression of renal damage by inhibiting tubulointerstitial fibrosis.Introduction
Unilateral ureteral obstruction (UUO) is a well-established
in vivo model of tubulointerstitial scarring. It involves
virtually all renal intrinsic and infiltrating cells and is
characterized by alterations in their phenotype and ac-
cumulation of excessive extracellular matrix proteins* Correspondence: amp97@yuhs.ac
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unless otherwise stated.[1-4]. Another histologic alteration frequently noted in
UUO is rarefaction of peritubular capillaries (PTC) that
are essential for providing nutrients and oxygen to the
surrounding tubules and interstitial cells [5,6]. Renal
microvasculature injury leading to PTC rarefaction and
resulting in chronic tissue hypoxia is a major contribu-
tor to renal disease progression [7]. Recently, myofibro-
blasts have been shown to rise from endothelial cells via
endothelial-to-mesenchymal transition (EndoMT) induced
by the transforming growth factor-β (TGF-β) family of
regulatory polypeptides in experimentally induced fibroticis is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/4.0), which permits unrestricted use, distribution, and
iginal work is properly credited. The Creative Commons Public Domain
g/publicdomain/zero/1.0/) applies to the data made available in this article,
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EndoMT may play an important role in the process of
kidney fibrosis in UUO [8].
We previously demonstrated that kidney-derived mes-
enchymal stem cells (KMSCs) are capable of homing to
injured renal tubulointerstitium after acute ischemic-
reperfusion injury and inducing tissue repair via secretion
of proangiogenic factors, such as vascular endothelial
growth factor (VEGF)-A. Administration of MSCs pre-
vented the loss of PTC possibly due to local production of
growth factors, rather than by differentiation into renal
cells, and the maintenance of interstitial vasculature was
associated with less interstitial fibrosis [9]. The paracrine
actions of MSC administration were recently demon-
strated to involve the release of microparticles (MPs) by
MSCs. These MSC-derived MPs play important roles in
cell-to-cell communication via transportation of various
mRNA or proteins and interact via specific receptor li-
gands to exert their protective effects [10-12]. In a previ-
ous study, KMSC-derived MPs delivered proangiogenic
signals and contributed to recovery of renal function in
acute ischemia-reperfusion injury [13]. MSC-derived MPs
afforded renoprotective effects in various models of acute
kidney injury by ameliorating apoptosis of tubular epithe-
lial cell and stimulating tubular epithelial cell proliferation
[10,14]. However, studies have yet to demonstrate the effi-
cacy of KMSC-derived MPs in preventing renal fibrosis
and PTC rarefaction in an in vivo model of tubulointersti-
tial scarring.
In this study, we assessed the effect of KMSC-derived
MPs on the development of renal fibrosis in a murine
model of UUO. Moreover, we investigated the mechan-
ism by which KMSC-derived MPs exert their PTC pro-
tective effects, focusing on EndoMT.
Methods
Culture of mouse kidney mesenchymal stem cells and
isolation of microparticles
We previously isolated and cloned a fibroblast-like cell line
from the kidneys of adult FVB/N mice [15]. These KMSCs
were cultured on gelatin-coated dishes in minimum essential
medium (MEM) with 10% horse serum (Gem Biotech,
Woodland, CA, USA) as previously described [15]. For
generation of MPs, culture medium was replaced with
serum free alpha MEM, and KMSCs were then placed in a
hypoxic chamber (<1% O2) for 24 hours. Cell debris was
removed by centrifugation at 1,000 g for 10 minutes at room
temperature. The cell-free supernatants were centrifuged at
50,000 g (Beckman Coulter Optima L-90 K ultracentrifuge)
for two hours at 4°C and washed in phosphate-buffered
saline (Sigma, St Louis, MO, USA) with a second centrifuga-
tion under the same conditions. The supernatants collected
from the second ultracentrifugation washing (‘Vehicle
control’) were used for in vitro experiments, such asEndoMT and proliferation assay of TGF-β1-treated
human umbilical vein endothelial cells (HUVECs).
Thereafter, MPs from KMSCs were labeled with PKH26
dye (Sigma) or cell-tracker (Invitrogen, Carlsbad, CA,
USA) for tracing in vivo and in vitro experiments. MPs
were identified by fluorescence microscopy (Carl Zeiss,
Göttingen, Germany) or fluorescence-activated cell sorting
(FACS) analysis (BD Canto II, Franklin Lakes, NJ, USA)
and electron microscopy (JEM-1011, Tokyo, Japan) as
previously described [13].
To abolish mRNA-dependent effects, MPs were preincu-
bated with 1 U/ml RNase (Ambion Inc., Austin, TX, USA)
for one hour at 37°C; the reaction was stopped by addition
of 10 U/ml RNase inhibitor (Ambion Inc.).
The protein content of MPs was quantified by the
Bradford method (BioRad, Hercules, CA, USA).
In vitro cell proliferation assay and TGF-β-induced
endothelial-to-mesenchymal transition in cultured human
umbilical vein endothelial cells
HUVECs were purchased from Lonza (Walkersville, MD,
USA) and cultured on endothelial growth medium (EGM)
(Lonza) with 20% fetal bovine serum (FBS; Lonza) and 1%
penicillin/streptomycin (Gibco, Carlsbad, CA, USA). Cells
between passages two and six were used. To test cell via-
bility, we used an EZ-Cytox Cell Viability Assay Kit (Daeil
Lab Service Co, Seoul, Korea). The assay is based on the
cleavage of tetrazolium salt to water-soluble formazan by
the succinate-tetrazolium reductase system which belongs
to the respiratory chain of the mitochondria and is active
only in viable cells. Therefore, the amount of the formazan
dye is directly proportional to the number of living cells.
HUVEC were seeded at 5,000 cells/well into 96-well plates
in EBM-2 media (Lonza) deprived of FBS. After 36 hours,
we added 20 μl of EZ-Cytox kit reagent into each cell cul-
tured well of a 96-well microplate and incubated at 37°C,
in 5% CO2 incubator for 90 minutes. Cell viability at base-
line was measured using a microplate reader at 450 nm.
Recombinant TGF-β1 was used at a concentration of
5 ng/ml as previously reported [16] for in vitro cell prolifera-
tion assay and EndoMT experiments in cultured HUVEC.
KMSC-derived MPs (20 ug for in vitro cell proliferation
assay, 1 to approximately 2 × 107/well for EndoMT) were
added to each well.
Western blot analysis
For in vitro cellular experiments, cells were lysed with
radioimmunoprecipitation assay (RIPA) buffer (20 mM
Tris, pH 7.8, 140 mM NaCl, 1 mM ethylenediaminetet-
raacetic acid (EDTA), 1% Triton X-100, 0.1% SDS, 1%
sodium deoxycholate, 1 mM NaF, and 1 mM ortho-
vanadate) with Complete Mini protease inhibitors
(Roche, Indianapolis, IN, USA). Protein concentration
was determined using a Bradford assay (Bio-Rad).
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SDS-PAGE gels and transferred to Immobilon-P mem-
branes (Millipore, Bedford, MA, USA). Following blocking
with TBS/5% nonfat dry milk, membranes were incubated
with the following primary antibodies: anti-α-SMA (1:1,000;
Sigma), β-actin (1:1,000; Cell Signaling, Danvers, MA,
USA), and anti-CD31 (1:2,000; Abcam, Cambridge, UK).
Following washes with TBS/0.1% Tween 20, membranes
were incubated with horseradish peroxidase-conjugated
secondary antibodies (Santa Cruz, Dallas, TX, USA) for
60 minutes at room temperature. The analysis was re-
peated in triplicate to ensure the reproducibility of results.
Membranes were washed and protein was detected by
chemiluminescence.
The intensity of the band of CD31 and α-smooth
muscle actin (α-SMA) proteins from western blots was
quantified by using NIH Image J 1.34 s software and
normalized to β-actin.
Mouse model of unilateral ureteral obstruction
The animal study protocol was designed in accordance with
the guidelines for use of laboratory animals and approved
by the Institutional Animal Care and Use Committee of
Yonsei University Healthcare System (IACUC approval
number: 2010-0302-1). Adult (eight to ten weeks old) FVB/
N mice were purchased from The Koatech (Gyeonggi-Do,
Korea). Animals were kept under temperature-controlled
conditions with a 12-hour light/dark cycle, with water and
food ad libitum. The experiments were designed to test the
hypothesis that exogenous administration of MSC-derived
MPs would ameliorate progressive tubulointerstitial scar-
ring and PTC loss, characteristic of UUO models. UUO
was performed using an established protocol [17]. Briefly,
mice were anesthetized with intraperitoneal injection of a
combination of Zoletil (20 mg/kg) and xylazine (10 mg/
kg) and placed on a heated surgical thermo plate (Jeung
Do Bio & Plant Co, Seoul, Korea). The left ureter was vi-
sualized via a flank incision and ligated with 3-0 silk at
two points just below the lower pole of the left kidney; the
wound was closed in layers. Following UUO, mice were
randomly divided into four experimental groups (n = 5)
and administered the following agents via the tail vein: ve-
hicle (saline) only, KMSCs (1 × 106 per mouse), KMSC-
derived MPs (2 × 107 per mouse), or RNase treated MPs.
In each group, mice were sacrificed at day 7 after UUO (n
= 5 per group). The kidneys were subsequently removed
and renal tissues were analyzed for localization of MPs
and markers of renal fibrosis or PTC rarefaction.
Immunohistochemical and immunofluorescent analysis
For analysis of kidney fibrosis, kidney sections were stained
with Masson’s trichrome and anti-α-SMA (Sigma). Positive
areas of Masson’s trichrome and α-SMA staining were
evaluated in relation to the unit area and expressed as apercentage per unit area using MetaMorph microscopy
image analysis software (Molecular Devices, Sunnywale,
CA, USA). Microscopic assessment was carried out in a
blinded manner and 20 randomly selected fields from each
slide section were examined at ×400 magnification.
Immunohistochemistry for detection of proliferation and
rarefaction of PTC was performed as described previously
[18]. Kidney sections were labeled with anti-CD31 (Santa
Cruz) and anti-PCNA (proliferating cell nuclear antigen,
Millipore). Immunoperoxidase staining was performed
using a 1:100 dilution of anti-rabbit horseradish peroxidase
(HRP, Abcam) or anti-mouse IgM (Invitrogen). Scoring for
CD31 and PCNA-positive cells was determined by counting
the number of positive nuclei per high-power field (HPF) in
10 randomly chosen fields through the kidney specimens.
Quantification of PTC loss was performed by calculating
the rarefaction index as previously described [18]. Briefly,
the CD31-immunostained sections were examined across a
10 × 10 grid under a × 40 objective. Each square within the
grid that did not contain CD31-positive capillaries was
counted. At least 20 fields in the cortex and outer medulla
were examined on the cross-section of each kidney, and a
mean score per section was calculated. This scoring system,
thus, inversely reflects PTC rarefaction, whereby low values
represent intact capillaries and higher values indicate loss of
capillaries (the minimum possible capillary score is 0, and
the maximum score is 100).
Immunohistochemistry for macrophages was con-
firmed using anti-F4/80 (Abcam). The quantification of
F4/80-positive cells was expressed as number of cells per
HPF [19].
Colocalization of CellTracker™-labeled MPs within the
peritubular interstitium was demonstrated by detecting
green fluorescent CellTracker™ and the presence of red
fluorescent CD31 (Santa Cruz) in kidney sections
by confocal microscopy (LSM 780, Carl Zeiss, Jena,
Germany) using × 40 fluorescence objective lens and
analyzed with LSM5 software.
The detection of EndoMT was performed as previously
described [20]. Kidney sections were labeled with anti-
CD31 (Santa Cruz) and anti-α-SMA (Sigma). The second-
ary antibodies included Alexa Fluor 488- (Jackson, West
Grove, PA, USA) and Cy3–(Jackson) conjugated second-
ary antibodies. At least 15 randomly selected fields were
analyzed for co-localization of endothelial and fibroblast
markers by confocal microscopy (LSM 780, Carl Zeiss,
Jena, Germany).
To detect cell apoptosis in the UUO kidney, terminal
deoxynucleotidyl transferase-mediated dUTP nick end-
labeling (TUNEL) assays were performed using an In
Situ Cell Death Detection Kit (Roche, Indianapolis, IN,
USA). Positive nuclei in the field were examined under a
confocal microscope (LSM 780, Carl Zeiss, Jena, Germany)
using a × 40 fluorescence objective lens and analyzed with
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cortex and corticomedullary junction on each slide section
were examined as previously reported [13].
Statistical analysis
Data are expressed as mean ± s.e.m. Differences between
the groups were analyzed by analysis of variance or the
Kruskal–Wallis test using SPSS software version 20.0
(SPSS, Chicago, IL, USA). All P-values less than 0.05
were considered statistically significant.
Results
KMSC-derived MPs attenuate TGF-β1-induced EndoMT of
HUVEC in vitro
First, we confirmed the incorporation of MPs which
were pre-incubated with PKH26 dye for 30 minutes atFigure 1 Incorporation of PKH26-labeled MPs into cultured HUVEC an
transition. Immunofluorescence microscopy revealed that red PKH26-labe
DAPI staining (A), white arrows). Light microscopy analysis shows the morp
and KMSC-derived MPs simultaneously, compared to non-treated control c
tein expression levels in HUVEC treated with vehicle control or KMSC-deriv
protein expression levels normalized by β-actin protein expression measure
as ‘Control’. Vehicle control of MPs comprised MP-free supernatants after c
as the mean ± SE of three different experiments. The Kruskal-Wallis test was
TGF-β1 alone. DAPI, 4',6-diamidino-2-phenylindole; HUVEC, human umbilica
MPs, microparticles; SE, standard error; TGF-β1, transforming growth factor-37°C into cultured HUVEC by immunofluorescence mi-
croscopy analysis (Figure 1A). To investigate the effects
of KMSC-derived MPs on EndoMT, cultured HUVEC
were treated with a predetermined concentration of
TGF-β1. We found that TGF-β1 treatment in cultured
HUVEC led to morphological changes into a fibroblast-
like spindle-shaped form compared to the cobble stone
appearance of non-treated controls, and these changes
were inhibited by KMSC-derived MPs (Figure 1B). Next,
we checked CD31 and α-SMA protein expression levels
in HUVEC treated without or with TGF-β1. Western
blot analysis revealed significant decreases in CD31 protein
expression in HUVEC treated with TGF-β1, compared to
non-treated control cells (CD31/β-actin: 0.32 ± 0.01 versus
0.73 ± 0.04, P <0.05), while incubation with KMSC-derived
MPs inhibited this effect (CD31/β-actin: 0.68 ± 0.03,d the in vitro effect of MPs on endothelial-to-mesenchymal
led MPs were readily incorporated into cultured HUVEC, as shown by
hologic changes of HUVEC treated with TGF-β1 alone or with TGF-β1
ells (‘Control’) (B). Western blot analysis shows CD31 and α-SMA pro-
ed MPs. (C). A bar graph shows the quantification of CD31 and α-SMA
d using the Image J program (D). Non-treated control was expressed
entrifugation was expressed as ‘Vehicle control.’ Results are expressed
performed; * P <0.05 versus non-treated control. # P <0.05 versus
l vein endothelial cells; KMSC, kidney-derived mesenchymal stem cells;
β1; α-SMA, α-smooth muscle actin.
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β1 treatment significantly increased α-SMA protein
expression in HUVEC compared to non-treated con-
trol cells (α-SMA/β-actin: 0.41 ± 0.05 versus 0.07 ±
0.00, P <0.05). This effect was significantly attenuated
by treatment with KMSC-derived MPs (α-SMA/β-actin:
0.22 ± 0.00 versus TGF-β1 treatment). Vehicle control
which was MP-free supernatants had no effect on the
EndoMT induced by TGF-β1 treatment (Figure 1C, D).
In vitro proliferative effects of KMSC-derived MP on
HUVEC
We further evaluated the in vitro proliferative effects of
KMSC-derived MPs on HUVEC. Incubation of HUVEC
with TGF-β1 significantly reduced the proliferation of
HUVEC compared to non-treated control cells. KMSC-
derived MPs significantly improved the proliferation of
HUVEC in serum deprived culture conditions, com-
pared to non-treated control cells, or TGF-β1 treated
cells (relative degree of proliferation compared to non-
treated control cells; KMSC-MPs 196.5 ± 4.7 versus
TGF-β1 80.3 ± 4.0%, P <0.05). KMSC-derived MPs that
were preincubated with RNase (MP-RNase) failed to
demonstrate this beneficial effect on cell proliferation in
cultured HUVEC (Figure 2).
In vivo engraftment of MPs into PTC in UUO kidneys
Next, we investigated the engraftment of KMSC-MPs in
UUO kidneys. The green CellTracker™ labeled MPs were
injected into FVB/N mice via the tail vein immediately
after UUO and mice were sacrificed at day 7 afterFigure 2 In vitro cell proliferation effects of MPs. Cell proliferation of H
with TGF-β1 treatment simultaneously with KMSC-derived MP, and MPs pre
Results are expressed as the mean ± SE of three different experiments. The
# P <0.05 versus TGF-β1 alone. HUVEC, human umbilical vein endothelial c
SE, standard error; TGF-β1, transforming growth factor- β1.KMSC-MP injection. The green CellTracker™ labeled
MPs were visualized in the UUO kidneys. These labeled
MPs were also observed within the PTC expressing
CD31 in confocal microscopy analysis (Figure 3A).
Semi-quantitative analysis revealed that the average
number of engrafted MPs in the UUO kidney (‘Total
MPs’) or within the PTC (‘PTC MPs’) was 20.1 ± 1.0
MPs per mm2 and 6.3 ± 0.8 MPs per mm2, respectively
(Figure 3B). No labeled MPs were detected in contralat-
eral kidneys (data not shown).KMSC-derived MPs ameliorate tubulointerstitial fibrosis in
UUO kidney
To explore the anti-fibrotic effect of KMSC-derived MPs,
we examined kidney sections stained with Masson’s tri-
chrome and α-SMA in UUO kidneys treated with KMSC,
KMSC-derived MPs, vehicle and MP-RNase. At day 7
after UUO injury, Masson’s trichrome staining showed
more fibrotic lesions in the UUO kidneys injected with ve-
hicle control. In contrast, KMSC or KMSC-derived MP
injected mice kidneys showed less fibrosis in tubulointer-
stitial areas compared to kidneys injected with vehicle
control or RNase-treated MPs (11.5 ± 0.8, 7.7 ± 0.6 versus
29.4 ± 4.8, 21.6 ± 1.6% of total tubulointerstitial area, re-
spectively, *P <0.05) (Figure 4A, B). The kidney sections
stained with α-SMA demonstrated similar findings as
those for Masson’s trichrome staining. The UUO mice
injected with vehicle control or MP-RNase showed in-
creased α-SMA staining compared to that for UUO mice
treated with KMSC or KMSC-derived MPs (29.4 ± 14.3,UVEC non-pretreated control (‘Control’), pretreated with TGF-β1 alone,
incubated with RNase. Non-treated control was expressed as ‘Control.’
Kruskal-Wallis test was performed; * P <0.05 versus non-treated control.
ells; KMSC, kidney-derived mesenchymal stem cells; MPs, microparticles;
Figure 3 In vivo engraftment of MPs in UUO kidneys. Confocal laser microscopy confirms peritubular capillaries stained with anti-CD31 and
the engraftment of green CellTracker™ labeled MPs in peritubular capillaries. White bar represents 20 μm. White arrows indicate the engraftment
of green CellTracker™ labeled MPs into peritubular capillaries (A). Semi-quantitative analysis shows the number of engrafted MPs in UUO kidneys
(‘Total MPs’) or within the peritubular capillaries (‘PTC MPs’) (B). MPs, microparticles; UUO, unilateral uretal obstruction.
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stitial area, respectively, *P <0.05) (Figure 4A, B).
Next, we investigated the anti-inflammatory effects of
KMSC or KMSC-derived MPs on UUO kidney. Immu-
nohistochemistry for macrophages using F4/80 antibody
confirmed increased macrophage infiltration in the tubu-
lointerstitial area in UUO kidney. The number of F4/80-
positive cells per HPF was counted in 10 randomly chosen
sections. At seven days after UUO injury, the F4/80-posi-
tive cells were increased in mice kidneys treated with ve-
hicle control. Administration of KMSC or KMSC-derived
MPs reduced F4/80-positive cells compared to administra-
tion of vehicle control or RNase-treated MPs (36.3 ± 2.9,
33.8 ± 3.4 versus 130.8 ± 1.5, 111.7 ± 15.2 per field, respect-
ively, *P <0.05) (Figure 4A, B).
To further examine the renoprotective mechanisms of
KMSC-derived MPs, the degree of renal cell prolifera-
tion and microvascular density were examined in the
kidneys of control, KMSC, MPs, and MP-RNase injected
mice. The total number of PCNA-positive renal cells
was significantly greater in mice kidneys injected with
KMSC and KMSC-derived MPs than kidneys injected
with vehicle or MP-RNase (34.7 ± 6.1, 42.8 ± 4.4 versus
15.8 ± 2.9, 24.3 ± 3.0 per field, respectively, *P <0.05)
(Figure 5A, B). The degree of renal microvascular rarefac-
tion assessed by CD31 expression was significantly less in
mice injected with KMSC and KMSC-derived MPs than
in control or MP-RNase injected mice (9.8 ± 1.6, 15.3 ± 2.9versus 48.8 ± 4.1, 44.7 ± 4.2 per field, respectively, *P <0.05)
(Figure 5A, B).
The anti-apoptotic effects of MPs on UUO injury were
evaluated by TUNEL staining. At day 7 after UUO in-
jury, there were significantly fewer TUNEL positive
apoptotic nuclei in UUO kidneys injected with either
KMSC or KMSC-derived MPs than those injected with
vehicle or RNase-treated MPs (0.4 ± 0.3, 1.4 ± 0.5 versus
55.4 ± 5.7, 64.6 ± 5.1 cells per HPF respectively, *P <0.05)
(Figure 5A, B). Apoptotic PTC endothelial cells coex-
pressed CD31 and TUNEL. The total number of TUNEL
positive PTC endothelial nuclei was also significantly re-
duced in UUO kidneys treated with KMSC or KMSC-
derived MPs compared to mice injected with vehicle
control or RNase-treated MPs (0.2 ± 0.2, 1.0 ± 0.6 versus
13.8 ± 1.2, 11.8 ± 0.6 cells per HPF, respectively, *P <0.05)
(Figure 5A, B).
We next investigated whether KMSC-MPs demon-
strated local anti-apoptotic effects in UUO kidneys. Red
CellTracker™ labeled MPs were infused into UUO mice
immediately after the procedure, and we used confocal
microscopy to analyze kidney regions in UUO mice in
which red CellTracker™ labeled MPs were present or not
for apoptotic cells shown by TUNEL staining. Regions
containing red CellTracker™ labeled MPs (white arrows)
did not show apoptotic cells (green nuclei, yellow ar-
rows), compared to regions without red CellTracker™ la-
beled MPs, thereby suggesting that these regions were
Figure 4 Anti-fibrotic effects of KMSC or KMSC-derived MPs in UUO kidneys. Light-field microscopic analysis of Masson’s trichrome–stained
sections of UUO kidneys treated with vehicle control, KMSC, KMSC-derived MPs, or MP-RNase (A). Quantitative analysis of tubulointerstitial fibrosis
in Masson’s trichrome–stained sections using the Image J program (B, upper panel). Immunohistochemical study for α-SMA expression in UUO
kidneys treated with vehicle control, KMSC, KMSC-derived MPs, or MP-RNase (A). Quantitative analysis of tubulointerstitial α-SMA–positive area
sections using the Image J program (B, middle panel). Immunohistochemical study for F4/80 positive cells in UUO kidneys treated with vehicle
control, KMSC, KMSC-derived MPs, or MP-RNase (A). Quantification analysis of F4/80 positive cells per field (B, lower panel). Ten randomly selected
high-power fields were quantified and averaged to obtain the value for each mouse (n = 6 for each experimental group). Results are expressed as
the mean ± SE of three different experiments. The Kruskal-Wallis test was performed; * P <0.05 versus vehicle control. Black bar represents 50 μm.
KMSC, kidney-derived mesenchymal stem cells; MPs, microparticles; SE, standard error; UUO, unilateral uretal obstruction; α-SMA, α-smooth
muscle actin.
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TUNEL-stained kidneys at high-power fields (×20)
showed a significantly lower number of apoptotic cells
in fields containing MPs, compared to fields without
MPs (0.3 ± 0.2 versus 3.7 ± 0.7 cells per HPF, respectively,
P <0.05) (Figure 6B).
In vivo effect of microparticles on EndoMT in UUO
kidneys
Next, we performed double staining for α-SMA positive
fibroblasts with CD31 to show whether KMSC and
KMSC-derived MPs exert in vivo effects on EndoMT in
UUO kidneys. Confocal microscope analysis revealed the
existence of α-SMA positive fibroblasts with CD31 in
UUO kidneys treated with vehicle control or MP-RNase.By semi-quantitative analysis, the number of α-SMA
positive fibroblasts with CD31 was significantly less in
mice kidneys injected with KMSC and KMSC-derived
MPs than mice injected with vehicle or MP-RNase (12.0
± 1.5, 10.5 ± 0.8 versus 39.4 ± 2.1, 43.8 ± 3.4 cells per
HPF, respectively, *P <0.05) (Figure 7A, B). These find-
ings suggested that administration of KMSC and KMSC-
derived MPs in UUO kidneys offers beneficial effects on
UUO injury via inhibition of EndoMT of PTC endothe-
lial cells.
Discussion
In the present study, we demonstrated that MPs adminis-
tered following UUO localized within PTC and these MPs
significantly decreased EndoMT, enhanced endothelial cell
Figure 5 Proliferation, microvascular rarefaction, and apoptosis in UUO kidneys. Immunohistochemistry analysis showed representative
images of CD31 and PCNA staining in UUO kidneys treated with vehicle control, KMSC, KMSC-derived MP, and MP-RNase (A, upper panel, CD31;
brown color, PCNA; red color). Quantitative analysis of PCNA-positive cells (black arrows) per field in UUO kidneys. The PCNA-positive counting
was used to assess the proliferation of tubular epithelial cells and peritubular capillaries (B). Quantitative analysis of PTC rarefaction index was
determined by CD31 staining (B). Representative images of TUNEL and CD31 staining in UUO kidneys by confocal laser microscope analysis
(A, lower panel, CD31; red color, TUNEL; green color). Quantitative analysis demonstrates the total number of TUNEL-positive nuclei and both
TUNEL and CD31-positive PTC nuclei (white arrows) in UUO kidneys injected with KMSCs and KMSC-derived MPs, compared to those injected
with vehicle control or MP-RNase. Results are expressed as the mean ± SE of six different experiments. The Kruskal-Wallis test was performed;
* P <0.05 versus vehicle control (B). Black bar represents 50 μm. White bar represents 20 μm. KMSC, kidney-derived mesenchymal stem cells; MPs,
microparticles; PCNA, proliferating cell nuclear antigen; PTC, peritubular capillaries; SE, standard error; TUNEL, terminal deoxynucleotidyl
transferase-mediated dUTP nick end-labeling; UUO, unilateral uretal obstruction.
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creased rarefaction of PTC. Administration of MPs also
inhibited infiltration of inflammatory macrophages (F4/80
positive) and decreased tubulointerstitial fibrosis. MPs
preincubated with RNase did not show the same protect-
ive effects, suggesting that the renoprotective effects of
the MPs were mediated in a manner at least partially
dependent on mRNA transfer to target cells.
We recently demonstrated that MPs derived from
KMSCs cultured in anoxic conditions express high levels
of proangiogenic VEGF-A mRNA. When these MPs
were administered following acute ischemia-reperfusion,
the MPs localized into tubular cells as well as PTC
endothelial cells, and resulted in significant ameliorationof PTC rarefaction and improvement in renal function
[13]. Similarly, the present study showed that KMSC-
derived MPs stained with CellTracker™ engrafted in PTC
in UUO kidneys and the administration of KMSC and
KMSC-derived MPs improved renal microvascular rar-
efaction and endothelial cell proliferation. Moreover,
apoptosis of not only tubular epithelial cells but also
PTC endothelial cells was significantly reduced by injec-
tion of KMSCs or KMSC-MPs into UUO mice, and this
resulted in preservation of the peritubular microvascula-
ture. Interestingly, in vivo homing and engraftment of
KMSC-derived MPs was only observed in obstructed
kidneys. This suggests that homing and engraftment of
MPs into injured tissue also operates in an injury signal-
Figure 6 Anti-apoptotic effects of in vivo engrafted-MPs in UUO kidneys. Confocal laser microscopy confirms the engraftment of red
CellTracker™ labeled MPs and TUNEL staining in UUO kidneys. High-power fields in which red CellTracker™ labeled MPs (white arrows) were
present showed no apoptotic cells (TUNEL positive green nuclei, yellow arrows), compared to high-power fields without MPs (A). Quantitative
analysis demonstrates the total number of TUNEL-positive nuclei in high-power fields with or without MPs. Results are expressed as the mean ± SE of
six different experiments. The Kruskal-Wallis test was performed; * P <0.05 versus vehicle control (B). White bar represents 20 μm. MPs, microparticles;
SE, standard error; TUNEL, terminal deoxynucleotidyl transferase-mediated dUTP nick end-labeling; UUO, unilateral uretal obstruction.
Figure 7 Endothelial-to-mesenchymal transition in UUO kidney. Confocal laser microscopy analysis shows representative images of CD31
and α-SMA double-staining in UUO kidneys treated with vehicle control, KMSC, KMSC-derived MP, and MP-RNase (A, CD31; red color, α-SMA;
green color). Quantitative analysis of CD31 and α-SMA double-positive cells per field (white arrows) in UUO kidneys. Results are expressed as the
mean ± SE of six different experiments. The Kruskal-Wallis test was performed; * P <0.05 versus vehicle control (B). White bar represents 20 μm.
KMSC, kidney-derived mesenchymal stem cells; MPs, microparticles; SE, standard error; UUO, unilateral uretal obstruction; α-SMA, α-smooth
muscle actin.
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engraftment of MPs into injured tissue has not been ad-
dressed in the present study. However, as MPs have
comparable surface molecules as their cell of origin, it
would not be wrong to speculate that they would involve
adhesion molecules and ligands such as CD44, CD29,
α4-, α5-, and α6-integrins [13]. Importantly, analysis of
renal cortex and corticomedullary areas surrounding
engrafted MPs showed significantly lower numbers of
apoptotic cells, compared with areas that did not have
MPs. This suggests that MPs deliver anti-apoptotic sig-
nals into adjacent renal cells and possibly promote their
cellular survival. Similar results have been demonstrated
previously by Togel et al. in a rat model of ischemic in-
jury, where administration of bone marrow MSCs
homed to ischemic kidneys, and renal cells in the vicin-
ity of MSC showed less apoptosis [21]. Nevertheless, the
extent to which MPs are incorporated into target cells is
only 5 to approximately 20/mm2 of individual kidney
sections and the exact mechanism by which this small
number of MPs can induce reprogramming of their tar-
get cells is unknown. Furthermore, studies should be
performed to outline how MPs migrate from the blood
through the basal membrane into target cells in injured
kidneys.
To date, little is known of the exact mechanism for in-
ducing PTC endothelial cell loss. One possible mechanism
that has been intensively investigated is EndoMT, which
would increase fibroblast population while decreasing
endothelial cells. Endothelial lineage tracing, using Tie2-
Cre;R26R-stop-EYFP transgenic mice, confirmed the pres-
ence of up to 36% of EndoMT-derived fibroblasts in UUO
nephropathy [8]. In the present study, we demonstrated
that MPs significantly inhibited EndoMT of TGF-β1-
treated HUVEC. This effect was mediated by incorpor-
ation of KMSC-derived MPs and the resulting mRNA
transfer into target HUVEC as RNase pretreated MPs
failed to show any beneficial effect. Furthermore, adminis-
tration of KMSC-derived MPs immediately following
UUO significantly ameliorated EndoMT of PTC endothe-
lial cells and decreased the PTC rarefaction index. Con-
focal analysis showed that α-SMA positive fibroblasts co-
expressing CD31 were significantly decreased in UUO
mice injected with KMSC-derived MPs. To the best of our
knowledge, the present study is the first to demonstrate
that KMSC-derived MPs can inhibit EndoMT in vitro and
in vivo. Enhanced PTC endothelial cell proliferation or re-
duced endothelial cell apoptosis is another mechanism by
which KMSC-derived MPs may improve preservation of
PTC in UUO mice. Our previous study demonstrated that
incubation of HUVEC with KMSC-derived MPs promotes
a significant dose-dependent improvement in HUVEC
proliferation in serum deprived culture conditions [13]. In
accordance with our previous data, KMSC-derived MPssignificantly improved in vitro TGF-β1-treated HUVEC,
partly mimicking the microenvironment of PTC in UUO
mice kidneys. Thus, our present data are in strong support
of the notion that PTC rarefaction can be significantly
ameliorated upon treatment with KMSC-derived MPs.
Morphometric analysis revealed that KMSC-derived MPs
reduced interstitial infiltration of F4/80 positive macro-
phages or α-SMA positive (myo)fibroblasts and improved
renal fibrosis. Renal fibroblast proliferation and extracellu-
lar matrix production are driven in part by renal ischemia
[22]. The administration of KMSC-derived MPs into
UUO mice, via transfer of proangiogenic signals such as
VEGF-A, promoted endothelial cell proliferation and de-
creased EndoMT, resulting in significant increases in the
number of PTC. This preservation of PTC density in
UUO kidneys may have contributed to decreased intrare-
nal hypoxia and ameliorated inflammatory cell infiltration
and subsequent tubulointerstitial fibrosis [8].
One limitation of the present study is that, although
PTC as a whole showed increased density and less
EndoMT in UUO mice treated with KMSC-derived
MPs, we have no direct data to demonstrate the fate of
PTC endothelial cells that were engrafted with KMSC-
derived MPs. Such analysis would require cell fate tra-
cing experiments. Notwithstanding, in vitro HUVEC
experiments showed definite internalization of PKH26
labeled MPs into HUVEC and their proangiogenic effects.
In addition, kidney cells in the vicinity of engrafted MPs
showed significantly lower numbers of apoptotic cells
suggesting that MPs deliver anti-apoptotic signals into
adjacent renal cells to promote their cellular survival.
This ‘paracrine’ effect, therefore, could not be assessed
by morphometric analysis of surface labeled MPs. An-
other limitation is that expression of various proangio-
genic or anti-angiogenic molecules in the UUO kidneys
were not investigated after administration of KMSC-
derived MPs. VEGF-A, a predominant regulator of angio-
genesis, has been implicated as an important mediator in
preserving PTC in chronic kidney injury. In a rat model of
UUO, Ohashi et al. observed early PTC endothelial cell
proliferation that was accompanied by intense expression
of VEGF within the tubular epithelium [6]. In line with
this, deprivation of proangiogenic growth factors (for ex-
ample, VEGF) induced endothelial cell apoptosis. How-
ever, multiple studies report discrepancies, especially the
optimal time period of VEGF-A action and the expression
thereof in chronic kidney disease. Our previous studies
demonstrated that administration of KMSC-derived MPs
and KMSC into an acute ischemic injury mouse model ef-
fectively delivered VEGF-A mRNA and increased intrare-
nal VEGF-A expression up to five-fold, respectively [13].
As the focus of the present study was to investigate the
role of KMSC-derived MPs in EndoMT and their role in
protecting PTC density, investigation of expression of
Choi et al. Stem Cell Research & Therapy  (2015) 6:18 Page 11 of 12various angiogenic molecular targets in UUO mice treated
with KMSC-derived MPs would need a separate set of ex-
periments. Another limitation is that Masson’s trichrome
staining was used for the assessment of kidney fibrosis in
UUO kidneys. As trichrome stains basement membranes
and brush borders, the thickened or edematous basement
membranes of tubules might also be stained and thereby
assessed as kidney fibrosis [23].
Finally, the present study showed amelioration of
EndoMT in cultured HUVEC which exhibited the in-
corporation of red PKH26-labeled MPs. However, we
did not analyze in vivo EndoMT of endothelial cells
engrafted with MPs in UUO mice in comparison to
those that were not. Therefore, the present study might
have underestimated the beneficial effects of KMSC-
derived MPs on EndoMT in UUO kidneys. Also, since
we assessed in vivo EndoMT in cells only co-expressing
α-SMA and CD31 markers, we might have missed cells
that had already lost endothelial markers [8].
Conclusions
In summary, KMSC-derived MPs showed renoprotective
effects by ameliorating renal fibrosis, inflammation, and
EndoMT and preserving PTC endothelial cells in UUO
kidneys. Our data suggest that KMSC-derived MPs could
be a potential therapeutic approach against chronic renal
fibrosis.
Abbreviations
EndoMT: endothelial-to-mesenchymal transition; HPF: high-power field;
HUVEC: human umbilical vein endothelial cell; KMSC: kidney-derived
mesenchymal stem cell; MPs: microparticles; PCNA: proliferating cell nuclear
antigen; PTC: peritubular capillaries; TGF-β1: transforming growth factor-β1;
TUNEL: terminal deoxynucleotidyl transferase-mediated dUTP nick end-
labeling; UUO: unilateral ureteral obstruction; VEGF: vascular endothelial
growth factor; α-SMA: α-smooth muscle actin.
Competing interests
The authors declare that they have no competing interests.
Author’s contributions
HCP and HYC conceived and designed the experiments. SHA, AJ, ML, JEL
and HCP performed the experiments. HYC, HGL, BSK, HJK and SKH analyzed
and interpreted the data. HYC, JEL, HJK, and HCP wrote the paper. All
authors read and approved the final manuscript.
Acknowledgments
This study was supported by a grant of the Korea Health technology R&D
Project through the Korea Health Industry Development Institute (KHIDI),
funded by the Ministry of Health & Welfare, Republic of Korea (HI10C0644
(A100661)).
Author details
1Department of Internal Medicine, Gangnam Severance Hospital, Yonsei
University College of Medicine, Seoul, Korea. 2Severance Institute for Vascular
and Metabolic Research, Yonsei University College of Medicine, Seoul, Korea.
3Department of Microbiology and Immunology, Yonsei University College of
Medicine, Seoul, Korea. 4Department of Internal Medicine, Severance
Hospital, Yonsei University College of Medicine, Seoul, Korea. 5Department of
Internal Medicine, Yong-In Severance Hospital, Gyeongi-do, Korea.
6Department of Internal Medicine, CHA Bundang Medical Center, CHA
University, Gyeongi-do, Korea.Received: 10 October 2014 Revised: 19 February 2015
Accepted: 19 February 2015References
1. Chevalier RL, Forbes MS, Thornhill BA. Ureteral obstruction as a model of
renal interstitial fibrosis and obstructive nephropathy. Kidney Int.
2009;75:1145–52.
2. Park HC, Yasuda K, Ratliff B, Stoessel A, Sharkovska Y, Yamamoto I, et al.
Postobstructive regeneration of kidney is derailed when surge in renal stem
cells during course of unilateral ureteral obstruction is halted. Am J Physiol
Renal Physiol. 2010;298:F357–64.
3. Eddy AA. Molecular insights into renal interstitial fibrosis. J Am Soc Nephrol.
1996;7:2495–508.
4. Eitner F, Floege J. Novel insights into renal fibrosis. Curr Opin Nephrol
Hypertens. 2003;12:227–32.
5. Kang DH, Kanellis J, Hugo C, Truong L, Anderson S, Kerjaschki D, et al. Role
of the microvascular endothelium in progressive renal disease. J Am Soc
Nephrol. 2002;13:806–16.
6. Ohashi R, Shimizu A, Masuda Y, Kitamura H, Ishizaki M, Sugisaki Y, et al.
Peritubular capillary regression during the progression of experimental
obstructive nephropathy. J Am Soc Nephrol. 2002;13:1795–805.
7. Bohle A, Mackensen-Haen S, Wehrmann M. Significance of postglomerular
capillaries in the pathogenesis of chronic renal failure. Kidney Blood Press
Res. 1996;19:191–5.
8. Zeisberg EM, Potenta SE, Sugimoto H, Zeisberg M, Kalluri R. Fibroblasts in
kidney fibrosis emerge via endothelial-to-mesenchymal transition. J Am Soc
Nephrol. 2008;19:2282–7.
9. Ninichuk V, Gross O, Segerer S, Hoffmann R, Radomska E, Buchstaller A, et al.
Multipotent mesenchymal stem cells reduce interstitial fibrosis but do not
delay progression of chronic kidney disease in collagen4A3-deficient mice.
Kidney Int. 2006;70:121–9.
10. Gatti S, Bruno S, Deregibus MC, Sordi A, Cantaluppi V, Tetta C, et al.
Microvesicles derived from human adult mesenchymal stem cells protect
against ischaemia-reperfusion-induced acute and chronic kidney injury.
Nephrol Dial Transplant. 2011;26:1474–83.
11. Schorey JS, Bhatnagar S. Exosome function: from tumor immunology to
pathogen biology. Traffic. 2008;9:871–81.
12. Morel O, Toti F, Hugel B, Freyssinet JM. Cellular microparticles: a
disseminated storage pool of bioactive vascular effectors. Curr Opin
Hematol. 2004;11:156–64.
13. Choi HY, Moon SJ, Ratliff BB, Ahn SH, Jung A, Lee M, et al. Microparticles
from kidney-derived mesenchymal stem cells act as carriers of proangiogenic
signals and contribute to recovery from acute kidney injury. PLoS One.
2014;9:e87853.
14. Bruno S, Grange C, Deregibus MC, Calogero RA, Saviozzi S, Collino F, et al.
Mesenchymal stem cell-derived microvesicles protect against acute tubular
injury. J Am Soc Nephrol. 2009;20:1053–67.
15. Plotkin MD, Goligorsky MS. Mesenchymal cells from adult kidney support
angiogenesis and differentiate into multiple interstitial cell types including
erythropoietin-producing fibroblasts. Am J Physiol Renal Physiol.
2006;291:F902–12.
16. Zeisberg EM, Tarnavski O, Zeisberg M, Dorfman AL, McMullen JR, Gustafsson
E, et al. Endothelial-to-mesenchymal transition contributes to cardiac fibro-
sis. Nat Med. 2007;13:952–61.
17. Ishidoya S, Morrissey J, McCracken R, Reyes A, Klahr S. Angiotensin II
receptor antagonist ameliorates renal tubulointerstitial fibrosis caused by
unilateral ureteral obstruction. Kidney Int. 1995;47:1285–94.
18. Chen J, Park HC, Addabbo F, Ni J, Pelger E, Li H, et al. Kidney-derived
mesenchymal stem cells contribute to vasculogenesis, angiogenesis and
endothelial repair. Kidney Int. 2008;74:879–89.
19. Goncalves RG, Gabrich L, Rosario Jr A, Takiya CM, Ferreira ML, Chiarini LB,
et al. The role of purinergic P2X7 receptors in the inflammation and fibrosis
of unilateral ureteral obstruction in mice. Kidney Int. 2006;70:1599–606.
20. Zeisberg M, Yang C, Martino M, Duncan MB, Rieder F, Tanjore H, et al.
Fibroblasts derive from hepatocytes in liver fibrosis via epithelial to
mesenchymal transition. J Biol Chem. 2007;282:23337–47.
21. Togel F, Weiss K, Yang Y, Hu Z, Zhang P, Westenfelder C. Vasculotropic,
paracrine actions of infused mesenchymal stem cells are important to
the recovery from acute kidney injury. Am J Physiol Renal Physiol.
2007;292:F1626–35.
Choi et al. Stem Cell Research & Therapy  (2015) 6:18 Page 12 of 1222. Thomas SE, Anderson S, Gordon KL, Oyama TT, Shankland SJ, Johnson RJ.
Tubulointerstitial disease in aging: evidence for underlying peritubular
capillary damage, a potential role for renal ischemia. J Am Soc Nephrol.
1998;9:231–42.
23. Farris AB, Adams CD, Brousaides N, Della Pelle PA, Collins AB, Moradi E, et al.
Morphometric and visual evaluation of fibrosis in renal biopsies. J Am Soc
Nephrol. 2011;22:176–86.Submit your next manuscript to BioMed Central
and take full advantage of: 
• Convenient online submission
• Thorough peer review
• No space constraints or color ﬁgure charges
• Immediate publication on acceptance
• Inclusion in PubMed, CAS, Scopus and Google Scholar
• Research which is freely available for redistribution
Submit your manuscript at 
www.biomedcentral.com/submit
